Our Technology

Fast, robust discovery of in vivo matured monoclonal antibodies (hybridoma without limited dilution or subcloning).

HYBRIDOMAS

The expert team at Immunovive uses our proprietary robust immunization protocols that generate high serum titers to capture target-specific-producing B cells. These B cells are harvested and then fused together with myeloma cells, generating hybridoma colonies that produce high-affinity monoclonal antibodies of our chosen target at a single epitope. We efficiently screen 2,000+ clones to identify, select, and recover the best cells producing rare binders of our target of interest at a drug-like protein deliverable. Our discovery of positive hybridoma clones can be completed in 6 weeks.